Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies (ARC-8)

Summary

The purpose of this Phase 1, open-label, dose-escalation study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab, nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

General Information

NCT#: NCT04104672
Study ID: AB680CSP0002
Trial Phase: Phase I

Trial Sponsor: Arcus Biosciences, Inc.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, AB680, Zimberelimab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search